je.st
news
Tag: patients
FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
2015-12-18 22:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
treatment
expanded
New symptoms surface in Ebola patients months after initial recovery
2015-12-17 09:44:27| Biotech - Topix.net
Survivors of infection by Ebola virus, already known to face vision, hearing and other problems during their recovery, may also be plagued with health issues such as depression, anxiety and nerve damage that surface after they leave the hospital, according to a small spot survey of victims whose care was managed in the U.S. Some of the signs and symptoms can persist for months, researchers from the Centers for Disease Control and Prevention in Atlanta found. The data, reported in the New England Journal of Medicine, offer a snapshot of what eight patients, most of whom had been discharged at least four months earlier, had experienced - and were continuing to experience - during their recovery.
Tags: months
initial
surface
recovery
Remotely monitored patients up 51% to 4.9 mln in 2015
2015-12-07 14:59:00| Telecompaper Headlines
(Telecompaper) The number of remotely monitored patients grew by 51 percent to 4.9 million in 2015 as the market entered a growth phase fuelled by rising market acceptance in several key verticals, according to a report by Berg Insight. This number includes all patients enrolled in m-health care programmes in which connected medical devices are used as a part of the care regimen. Connected medical devices used for various forms of personal health tracking are not included in this figure. Researchers estimate that the number of remotely monitored patients will grow at a compound annual growth rate (CAGR) of 48.9 percent to reach 36.1 million by 2020. The two main applications are monitoring of patients with implantable cardiac rhythm management (CRM) devices and monitoring of patients with sleep therapy devices.
Tags: in
patients
monitored
remotely
Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA (pembrolizumab) Combined With Lenalidomide and Dexamethasone
2015-12-07 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today new study findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with lenalidomide and low-dose dexamethasone (two commonly used treatments for multiple myeloma) in patients whose disease has progressed after at least two lines of prior therapy, including a proteasome inhibitor and an IMiD (immune modulatory drug). Language: English Contact: Media:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: multiple
combined
observed
receiving
J&J leukemia drug cuts death risk vs. chemo in new patients: study
2015-12-07 03:47:40| Food - Topix.net
Johnson & Johnson's and AbbVie's cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine. In the trial of 269 patients aged 65 and older with chronic lymphocytic leukemia , Imbruvica decreased risk of death by a statistically significant 85 percent compared with the chemotherapy chlorambucil, researchers reported on Sunday.
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »